Applicant, as named in the Orange Book
Almirall
Next listed expiry: Seysara on 9 Feb 2033. 3 products with live protection, 3 without.
Products with listed protection
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Seysara · 3 strengths sarecycline hydrochloride | sarecycline hydrochloride | 209521 | 9 Feb 2033 | patent |
| Aczone dapsone | dapsone | 207154 | 18 Nov 2033 | patent |
| Klisyri tirbanibulin | tirbanibulin | 213189 | 7 Sep 2038 | patent |
Recent events
- 25 Oct 2026Aczone · Generic approved 25 Jun 2026
- 24 Oct 2026Altabax · Enters 12-month window basis: patent14 Feb 2027
Products without listed protection (3)
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Aczone dapsone | dapsone | 021794 | open now | no listed protection |
| Azelex azelaic acid | azelaic acid | 020428 | open now | no listed protection |
| Cordran flurandrenolide | flurandrenolide | 016455 | open now | no listed protection |